Hims & Hers Health (NYSE:HIMS) Shares Gap Down – Should You Sell?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) gapped down before the market opened on Thursday . The stock had previously closed at $68.74, but opened at $65.08. Hims & Hers Health shares last traded at $63.33, with a volume of 9,502,094 shares.

Analyst Ratings Changes

HIMS has been the subject of several research analyst reports. Bank of America lifted their target price on shares of Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a report on Thursday. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Finally, Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $42.00 to $60.00 in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.53.

Hims & Hers Health Stock Down 6.1 %

The stock’s 50 day moving average price is $33.94 and its 200-day moving average price is $25.19. The stock has a market capitalization of $14.10 billion, a PE ratio of 146.97 and a beta of 1.35.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 33,513 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $1,118,296.76. The trade was a 50.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Soleil Boughton sold 2,343 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total transaction of $70,055.70. Following the sale, the insider now directly owns 165,254 shares of the company’s stock, valued at $4,941,094.60. The trade was a 1.40 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,052,332 shares of company stock valued at $32,620,497. 17.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of HIMS. Public Employees Retirement System of Ohio purchased a new position in Hims & Hers Health during the 4th quarter worth approximately $99,000. Neo Ivy Capital Management raised its stake in shares of Hims & Hers Health by 145.4% during the 4th quarter. Neo Ivy Capital Management now owns 166,734 shares of the company’s stock valued at $4,031,000 after buying an additional 98,798 shares during the last quarter. PharVision Advisers LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $234,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Hims & Hers Health by 31.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,156 shares of the company’s stock valued at $8,225,000 after buying an additional 81,495 shares during the period. Finally, Two Sigma Advisers LP grew its holdings in Hims & Hers Health by 839.2% during the fourth quarter. Two Sigma Advisers LP now owns 524,100 shares of the company’s stock worth $12,673,000 after acquiring an additional 468,300 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.